Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide

BJU International

Volumn 86, Issue 9, 2000, Pages 1091-1092

  Yashi, M ^a,b   Muraishi, O ^a   Tokue, A ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Ohmori Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN RELEASING PEPTIDE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SMALL CELL CARCINOMA;

AGED; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDES; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034537048     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00951.x     Document Type: Article

References (4)

1. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59: 1152-9
2. Takada M, Kusunoki Y, Masuda N et al. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 1996; 73: 1227-32
3. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998; 51: 585-9
4. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-48